

3.3 – CARRYOVER BALANCES

Introduction

AGDUFA fees collected, appropriated, and not obligated at the end of a fiscal year remain available to FDA for use in future fiscal years. These funds are referred to as carryover balances. The operations in FY 2016 resulted in a net decrease of the carryover balance of \$54,498, which resulted in a year-end carryover balance of \$11,843,993.

Data

Table 3 captures FDA's carryover balances at the beginning and end of the 5-year authorization period for AGDUFA I and for each fiscal year to date under AGDUFA II.

Table 3 reflects the amount of fees collected net of any refunds or other adjustments that occurred during each fiscal year, for all cohort years combined, and the amount obligated during the fiscal year. The numbers do not include any accounts receivable. Therefore, the numbers for FY 2015 and FY 2016 in this table are different from the numbers in Table 1 in section 3.1 – User Fee Collections, which reflect the total net collections for the cohort years only.

Obligations in Table 3 include any recoveries and deobligations from prior years, which may cause differences from Tables 2 and 7. In FY 2016, FDA recovered \$3,320 in AGDUFA deobligations.

TABLE 3: ANIMAL GENERIC DRUG USER FEE COLLECTIONS, OBLIGATIONS, AND CARRYOVER BALANCES BY FISCAL YEAR

Program	Fiscal Years	Beginning Carryover	Net Collection	Obligations	Year-End Carryover
AGDUFA I	2009-2013	\$0	\$29,641,950	\$21,095,151	\$8,546,799
AGDUFA II	2014	\$8,546,799	\$8,088,825	\$6,158,667	\$10,476,957
	2015	\$10,476,957	\$10,115,060	\$8,693,526	\$11,898,491
	2016	\$11,898,491	\$8,853,989	\$8,908,486	\$11,843,993

Numbers have been rounded to the nearest dollar